TERN240920C15000
- 0.50
- 0.000.00%
Terns Pharmaceuticals Newsroom
Jefferies Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Maintains Target Price $22
Jefferies Sticks to Their Buy Rating for Terns Pharmaceuticals (TERN)
Analyst Forecasts Terns Pharmaceuticals' Upcoming CML Trial Data as Catalyst for Growth
Express News | Watching Shares Of Terns Pharmaceuticals; Traders Circulating Popular Newsletter Positively Mentioning The Company
Mizuho Securities Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Announces Target Price $10
JMP Securities Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Maintains Target Price $15
Buy Rating for Terns Pharmaceuticals Amid Forthcoming Milestones and Financial Stability
Terns Pharma Analyst Ratings
TD Cowen Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating
Terns Pharmaceuticals GAAP EPS of -$0.31
BMO Capital Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Maintains Target Price $19
Buy Rating Affirmed on Terns Pharmaceuticals Ahead of Key Clinical Data Releases and Strong Financial Standing
Terns Pharmaceuticals | 10-Q: Q2 2024 Earnings Report
Terns Pharma: Cash, Equivalents and Marketable Securities of $225 M, Expected to Provide Runway Into 2026 >TERN
Express News | Terns Pharmaceuticals Inc: Cash Runway Into 2026
Express News | Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates
Express News | Terns Pharmaceuticals Q2 Operating Expenses USD 25.537 Million
Express News | Terns Pharmaceuticals Q2 Income From Operations USD -25.537 Million Vs. IBES Estimate USD -27.9 Million
Express News | Terns Pharmaceuticals Q2 Basic EPS USD -0.31
Express News | Terns Pharmaceuticals Q2 Pretax Profit USD -22.675 Million Vs. IBES Estimate USD -26 Million